Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:00 AM ET. The event will be accessible via live webcast on their website's "Events and Presentations" page. A replay will be available for 30 days post-event. Deciphera specializes in developing innovative cancer treatments, with QINLOCK approved in several regions including the US, EU, and Australia. For more details, visit www.deciphera.com.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET.

A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK^® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005146/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

David.Rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When is Deciphera Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

Deciphera Pharmaceuticals will present on January 10, 2022, at 9:00 AM ET.

Where can I watch the Deciphera Pharmaceuticals presentation?

The presentation will be available via live webcast on Deciphera's "Events and Presentations" page.

What is QINLOCK, and where is it approved?

QINLOCK is Deciphera's treatment for fourth-line GIST, approved in the US, EU, Australia, and several other regions.

How long will the webcast replay of Deciphera's presentation be available?

The replay of the presentation will be archived for 30 days following the event.